Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors
Sílvia Marcé(Josep Carreras Leukaemia Research Institute), Fuensanta Millá, Javier Grau, Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Alberto Fernández de Sevilla(Duran i Reynals Hospital), Josep‐María Ribera(Universitat Autònoma de Barcelona), Lurdes Zamora(Universitat Autònoma de Barcelona), Marta Cabezón(Universitat Autònoma de Barcelona), C. Mauleón Fernández(Hospital Universitari de Girona Doctor Josep Trueta), Evarist Feliú(Universitat Autònoma de Barcelona), Concha Boqué(Institut Català d'Oncologia), José‐Tomás Navarro(Universitat Autònoma de Barcelona)
Cited by 11
Related Papers
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2016|457
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL
|Blood|2016|329
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309